US Stock MarketDetailed Quotes
AVDL Avadel Pharmaceuticals
- 11.660
- 0.0000.00%
Close Nov 22 16:00 ET
- 11.660
- 0.0000.00%
Post 16:20 ET
1.12BMarket Cap-15546P/E (TTM)
12.220High11.530Low1.58MVolume11.760Open11.660Pre Close18.66MTurnover1.86%Turnover RatioLossP/E (Static)96.36MShares19.09052wk High15.05P/B990.85MFloat Cap10.41052wk Low--Dividend TTM84.98MShs Float43.600Historical High--Div YieldTTM5.92%Amplitude0.710Historical Low11.836Avg Price1Lot Size
Avadel Pharmaceuticals Stock Forum
Sign in to post a comment
$Roblox (RBLX.US)$ $Anavex Life Sciences (AVXL.US)$ $Santech Holdings (STEC.US)$ $Lead Real Estate (LRE.US)$ $Avadel Pharmaceuticals (AVDL.US)$ $Carvana (CVNA.US)$ $Lemonade (LMND.US)$ $Autonomix Medical (AMIX.US)$ $Peloton Interactive (PTON.US)$ $PLBY Group (PLBY.US)$ $Alphatec (ATEC.US)$ $Universal Security Instruments (UUU.US)$ $Biofrontera (BFRI.US)$ $Root Inc (ROOT.US)$
🎃⚡️🎃
🎃⚡️🎃
5
3
$Avadel Pharmaceuticals (AVDL.US)$
Given its current financial standing and market movements, Avadel Pharmaceuticals is assessed as a moderately high-risk investment. The company's unprofitability, negative cash flow, and strong dependency on news-related catalysts pose potential risks. Nonetheless, the recently improved stock sentiment, coupled with analysts' positive forecasts, suggests some upside potential. The relatively high position in its volatility scale underscores the need for caution,...
Given its current financial standing and market movements, Avadel Pharmaceuticals is assessed as a moderately high-risk investment. The company's unprofitability, negative cash flow, and strong dependency on news-related catalysts pose potential risks. Nonetheless, the recently improved stock sentiment, coupled with analysts' positive forecasts, suggests some upside potential. The relatively high position in its volatility scale underscores the need for caution,...
8
$Sprouts Farmers Market (SFM.US)$ $J-Long Group (JL.US)$ $Confluent (CFLT.US)$ $Tenon Medical (TNON.US)$ $Adicet Bio (ACET.US)$ $Remitly Global (RELY.US)$ $Carvana (CVNA.US)$ $Avadel Pharmaceuticals (AVDL.US)$ $Alphatec (ATEC.US)$ $CPS Technologies (CPSH.US)$ $1847 Holdings (EFSH.US)$ $LuxUrban Hotels (LUXH.US)$ $Root Inc (ROOT.US)$
📊⚡️📊
📊⚡️📊
5
2
$Avadel Pharmaceuticals (AVDL.US)$ Reuters
4 mins ago
Avadel Pharmaceuticals Announces FDA Approval of Lumryz™ (Sodium Oxybate) Extended-Release Oral Suspension (Ciii) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older With Narcolepsy
4 mins ago
Avadel Pharmaceuticals Announces FDA Approval of Lumryz™ (Sodium Oxybate) Extended-Release Oral Suspension (Ciii) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older With Narcolepsy
1
📣 ITRM AdCom 9/9 meeting ongoing 🚗
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...
5
1
🚀 Buckle up for upcoming PDUFAs in September! 👇
$Travere Therapeutic (TVTX.US)$ : FILSPARI (Sparsentan)
$Avadel Pharmaceuticals (AVDL.US)$ : LUMRYZ (FT218)
$Iterum Therapeutics (ITRM.US)$ : Sulopenem - AdCom 🗓️
$Sanofi (SNY.US)$ & $Regeneron Pharmaceuticals (REGN.US)$ : Dupixent
$Vanda Pharmaceuticals (VNDA.US)$ : Tradipitant
$Zevra Therapeutics (ZVRA.US)$ : Arimoclomol
$Heron Therapeutics (HRTX.US)$ : ZYNRELEF® Vial Access Needle
$Merck & Co (MRK.US)$ : KEYTRUDA+ chemotherapy
$Bristol-Myers Squibb (BMY.US)$ : KarXT (...
$Travere Therapeutic (TVTX.US)$ : FILSPARI (Sparsentan)
$Avadel Pharmaceuticals (AVDL.US)$ : LUMRYZ (FT218)
$Iterum Therapeutics (ITRM.US)$ : Sulopenem - AdCom 🗓️
$Sanofi (SNY.US)$ & $Regeneron Pharmaceuticals (REGN.US)$ : Dupixent
$Vanda Pharmaceuticals (VNDA.US)$ : Tradipitant
$Zevra Therapeutics (ZVRA.US)$ : Arimoclomol
$Heron Therapeutics (HRTX.US)$ : ZYNRELEF® Vial Access Needle
$Merck & Co (MRK.US)$ : KEYTRUDA+ chemotherapy
$Bristol-Myers Squibb (BMY.US)$ : KarXT (...
10
4
🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
8
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Rockhoundj : $Cardio Diagnostics (CDIO.US)$
Is looking strong
Take a
Stock_Drift OP Rockhoundj : Agreed. Could be a good AH’s run!!?
Stock_Drift OP Rockhoundj : Let’s Go!!! $Cardio Diagnostics (CDIO.US)$